Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease-Reference-Cited by-同舟云学术

Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease

Published:1999-03 Issue:3 Volume:10 Page:311-316
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Coleman R.E.,Purohit O.P.,Black C.,Vinholes J.J. F.,Schlosser K.,Huss H.,Quinn K.J.,Kanis J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/10/3/311/19477299/10-3-311.pdf

Reference29 articles.

1. Treatment of malignancy-associated hypercalcemia with intravenous amino-hydroxypropylidene diphosphonate (APD);Body;J Clin Oncol,1986

2. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate;O’Rourke;Br J Cancer,1993

3. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy;Purohit;Br J Cancer,1995

4. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases;Hortobagyi;N Engl J Med,1996

5. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia®) infusions;Lipton;Proc ASCO,1997

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-06-24

2. Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis;Medicina;2021-08-26

3. SIMPLE SPECTROPHOTOMETRIC METHODS FOR ESTIMATION OF DRUGS AND PHARMACEUTICALS USING NBS-METHYL ORANGE DYE COUPLE;INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH;2019-09-01

4. Toxicity of Bone-Targeted Agents in Malignancy;Side Effects of Medical Cancer Therapy;2018

5. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials;BMJ Open;2015-06-02